TILT Biotherapeutics is a clinical-stage biotechnology company creating the next generation of immunotherapies for solid tumors.
TILT is reshaping cancer treatment by developing innovative investigational therapies that are intended to offer hope to patients with limited treatment options.
The patented TILT® technology includes modified viruses that are delivered intravenously and are able to reach cancer cells, helping the immune system recognize and attack solid tumors. Intravenous delivery offers the efficiency of the TILT® technology reaching the whole body, potentially targeting primary and metastatic tumors.
Boosting the Body’s Ability to Fight Cancer
For patients with solid tumors in whom immunotherapies have not been clinically effective, TILT is developing an investigational therapy that may offer an option.
Here’s how it works:
- TILT’s technology has been used in Phase I clinical studies in patients with different types of cancer to turn immunologically “cold” tumors (those lacking significant immune-cell infiltration) to “hot” tumors that are active sites for an immune response.
- TILT® technology consist of delivering proprietary oncolytic viruses armed with molecules like cytokines to cancer cells, to help stimulate and enhance T-cell (immune cell) responses.
- TILT-123 (igrelimogene litadenorepvec), company’s investigational therapy, is designed for intravenous administration and is the only engineered oncolytic virus armed with two immunostimulatory cytokines: tumor necrosis factor (TNF) and interleukin-2 (IL-2).
Discover more about how TILT’s technology works:
Pipeline
TILT has multiple oncolytic adenoviral immunotherapies for solid tumors in its pipeline. The lead investigational asset, TILT-123, is a Phase II ready intravenously delivered cytokine-armed adenoviral immunotherapy.
Partners
As a leading company developing oncolytic immunotherapies to enable T-cell therapy for solid tumors, the company collaborates with pharmaceutical companies to generate data on the potential of several combination therapy options.